Skip to content
The Nexus
BUSINESSJun 30 · 03:00 UTCSCMP CHINAJulie Zhang

Funding option: royalties giant opens Hong Kong base as mainland China biotech deals surge

The world’s largest biopharmaceutical royalties buyer has established its first Asia-Pacific base in Hong Kong as mainland Chinese biotech firms drive record out-licensing deals. Royalty financing is highlighted as an alternative capital-raising method amid US investment restrictions.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
the world’s largest buyer of biopharmaceutical royaltiesorganizationHong Kongplacemainland Chinese biotechnology firmsorganizationroyalty financingtopicUS investment restrictionstopicmultinational corporationsorganizationPharmaceutical Sectortopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting